Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Revised Rules For Japan’s Medical Devices Could Mean Speedier Time To Market

This article was originally published in PharmAsia News

Executive Summary

New rules separate medical devices from pharma regulations to provide clarity and regulatory efficiency, removing approval hurdles for devices and software in 2014.

You may also be interested in...

Japan’s 2014 Drug Price Reforms Extend Price Premium Program

The Japanese government has decided to revise its drug pricing policies starting in April 2014. Changes include extending a price premium program for two more years, bundling the pricing of similar generic drugs, and reduced pricing on long-listed drugs.

Novartis Launches Japan Compliance Advisory Board In Wake Of Diovan Turmoil

Novartis Pharma in Japan established a compliance advisory board as part of a move to salvage its tarnished image with ongoing Diovan scandals.

PMDA's Medical Information Project To Improve Adverse Effect Data In Japan

PMDA's project for developing a medical information database infrastructure for 10 million people aims to better understand the probability for adverse effects with drugs and will enter its test period starting next year.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts